Gerald L. Ray & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Gerald L. Ray & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$3.51M	Buy	+42,630	New	+$3.38M	0.44%	63
2016 Q2	–	Sell	-21,560	Closed	-$414K	–	306
2016 Q1	$414K	Sell	21,560 -700	-3%	-$14.8K	0.07%	202
2015 Q4	$779K	Sell	22,260 -9,820	-31%	-$633K	0.12%	148
2015 Q3	$2.95M	Sell	32,080 -1,000	-3%	-$86.5K	0.49%	55
2015 Q2	$2.91M	Sell	33,080 -100	-0.3%	-$8.56K	0.44%	60
2015 Q1	$2.46M	Sell	33,180 -500	-1%	-$35.3K	0.37%	69
2014 Q4	$1.89M	Buy	33,680 +13,500	+67%	+$710K	0.29%	86
2014 Q3	$915K	Buy	20,180 +3,970	+24%	+$166K	0.15%	133
2014 Q2	$671K	Buy	16,210 +11,210	+224%	+$577K	0.11%	161
2014 Q1	$346K	Buy	5,000 +700	+16%	+$51.4K	0.06%	227
2013 Q4	$259K	Buy	+4,300	New	+$234K	0.05%	247

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gerald L. Ray & Associates's CLVS Position: Q3 2017 in Review

Gerald L. Ray & Associates opened a new position in Clovis Oncology, Inc. (CLVS) in Q3 2017: 42,630 shares worth $3.51M. The stake represents 0.44% of the portfolio and ranks #63 among its holdings. This is a return to the name: Gerald L. Ray & Associates previously reported a position in CLVS as recently as Q1 2016.

Gerald L. Ray & Associates first reported a position in CLVS in Q4 2013 and has held it in 11 quarters since. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

Gerald L. Ray & Associates held 42,630 shares of Clovis Oncology, Inc. worth $3.51M as of Q3 2017.
Clovis Oncology, Inc. was a new Gerald L. Ray & Associates position in Q3 2017.
Clovis Oncology, Inc. made up 0.44% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #63 holding.
Gerald L. Ray & Associates first reported a position in Clovis Oncology, Inc. in Q4 2013 and has held it in 11 quarters since.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.